+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07658196

Safety and Dose Evaluation of ACM-CpG Intraperitoneal Therapy for Inoperable Peritoneal Metastases in Colorectal and Appendiceal Cancer

Led by Brown University · Updated on 2026-10-01

24

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of ACM-CpG therapy delivered by intraperitoneal injections for patients with inoperable peritoneal metastases or malignant ascites, particularly in colorectal or appendiceal adenocarcinoma cases. This phase 1 study uses escalating doses to find the maximum tolerated or optimal biologic dose, aiming to understand the treatments impact on this condition. Participants receive at least one dose of ACM-CpG therapy on the first day of a 28-day cycle, with the possibility of up to two additional injections if their disease remains stable or improves. The treatment doses increase through predefined levels, ranging from 0.1 mg to an optional 10 mg. The dosing follows a standard 33 design to carefully monitor safety and tolerability. During the trial, participants must visit the clinic regularly on Days 1, 4, 7, 10, 14, 21, and 28 for checkups and tests. Imaging scans such as CT or MRI will be performed every 8 weeks for three times, then every 12 weeks to monitor disease progression. Researchers are measuring treatment-emergent adverse events, progression-free survival, disease control rate, overall survival, and quality of life up to six months after treatment ends. The total participation duration includes treatment cycles and follow-up assessments.

CONDITIONS

Brief Title

TLR9 Immunotherapy for Peritoneal Carcinomatosis

Research Team

R

Roxanne Wood

E

Eligibility Screening

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here